Clinical trials: Thyroid Cancer Stage I
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer.
- Conditions
- BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
- Trial name
- NCT03975231
- Testing
- Dabrafenib, Intensity-Modulated Radiation Therapy, Trametinib
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center